<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354419</url>
  </required_header>
  <id_info>
    <org_study_id>2030.00</org_study_id>
    <secondary_id>NCI-2010-00191</secondary_id>
    <nct_id>NCT00354419</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant</brief_title>
  <official_title>A Dose Finding Study of Total Body Irradiation for Conditioning Patients With Severe Aplastic Anemia Transplanted With Umbilical Cord Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood&#xD;
      stem cell transplant helps stop the growth of abnormal cells. It also helps stop the&#xD;
      patient's immune system from rejecting the donor's stem cells. When the healthy stem cells&#xD;
      from a donor are infused into the patient they may help the patient's bone marrow make stem&#xD;
      cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells&#xD;
      from a donor can make an immune response against the body's normal cells. Giving cyclosporine&#xD;
      and mycophenolate mofetil before and after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of total-body&#xD;
      irradiation when given together with cyclophosphamide and antithymocyte globulin in treating&#xD;
      patients with severe aplastic anemia undergoing umbilical cord blood transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. The objective of this study is to determine the lowest dose of total body irradiation&#xD;
      combined with cyclophosphamide and antithymocyte globulin that will achieve sustained&#xD;
      engraftment in patients with severe aplastic anemia transplanted with unrelated umbilical&#xD;
      cord blood.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of total-body irradiation (TBI).&#xD;
&#xD;
      MYELOABLATIVE CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 to -4, -6&#xD;
      to -3, or -5 to -2 and antithymocyte globulin IV on days -6 to -4, -5 to -3, or -4 to -2.&#xD;
&#xD;
      TBI: Patients undergo TBI twice daily on days -3, -2, and/or -1.&#xD;
&#xD;
      UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT): Patients undergo UCBT on day 0. Patients receive&#xD;
      filgrastim (G-CSF) IV or subcutaneously beginning on day 1 and continuing until blood counts&#xD;
      recover.&#xD;
&#xD;
      GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive cyclosporine IV or orally (twice&#xD;
      daily for patients &gt;= 6 years of age or 3 times daily for patients &lt; 6 years of age) on days&#xD;
      -1 to +180 and mycophenolate mofetil IV or orally (twice daily for patients &gt;= 50 kg or 3&#xD;
      times daily for patients &lt; 50 kg) beginning 4 hours after UCBT and continuing until&#xD;
      approximately day +0.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
    <other_name>Enduxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>cord blood transplantation</other_name>
    <other_name>transplantation, umbilical cord blood</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow aspiration</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>granulocyte colony-stimulating factor</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Life-threatening marrow failure of nonmalignant etiology meeting two of the three&#xD;
             following criteria: granulocytes &lt; 500/mm^3; a corrected reticulocyte count &lt; 1%;&#xD;
             platelet count &lt; 20,000/mm^3&#xD;
&#xD;
          -  Failure to respond to the best available immunosuppressive treatment protocol by 75&#xD;
             days after initiation of therapy&#xD;
&#xD;
          -  Lack of an HLA-identical family member or closely matched (9 or 10 of 10 HLA-locus&#xD;
             match) unrelated marrow donor&#xD;
&#xD;
          -  DONOR: Unrelated UCB unit matched for at least 4 of 6 loci&#xD;
&#xD;
          -  DONOR: Related UCB unit matched for at least 3 of 6 lock&#xD;
&#xD;
          -  Selection of the UCB unit(s) will be based upon matching or mismatching at HLA-A, B&#xD;
             antigen level and DRB1 allele level typing; while HLA-C antigen/allele and HLA-DQB1&#xD;
             antigen/allele level typing are not considered in the matching criteria, if available&#xD;
             each may be used to optimize unit selection&#xD;
&#xD;
          -  Multiple UCB units are allowed to provide sufficient cell dose; when multiple units&#xD;
             are selected, the following rules apply: a) the UCB unit with the least HLA disparity&#xD;
             will be selected first (i.e., selection priority is 6/6 match &gt; 5/6 match &gt; 4/6&#xD;
             match), additional UCB units may be selected to increase cell dose; b) UCB units must&#xD;
             be matched to each other for at least 4 of 6 loci; c) each unit must contain at least&#xD;
             1.5 x 10^7 Total Nucleated Cells per kg recipient weight; d) the total cell dose of&#xD;
             the combined units must be at least 3.0 x 10^7 Total Nucleated Cells per kg recipient&#xD;
             weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe disease other than aplastic anemia that would severely limit the probability of&#xD;
             survival during the graft procedure; patients who present with active fungal&#xD;
             infections must be treated to resolve this problem before beginning the conditioning&#xD;
             regimen&#xD;
&#xD;
          -  HIV seropositive patients&#xD;
&#xD;
          -  Patients who have developed clonal cytogenetic abnormalities or a myelodysplastic&#xD;
             syndrome (these patients will be considered in separate protocols for myelodysplastic&#xD;
             syndrome, etc.)&#xD;
&#xD;
          -  Patients with paroxysmal nocturnal hemoglobinuria or Fanconi anemia&#xD;
&#xD;
          -  Patients &gt; 40 years of age&#xD;
&#xD;
          -  Related or unrelated cord blood units with &lt; 1.5 x 10^7 Total Nucleated Cells per kg&#xD;
             recipient weight&#xD;
&#xD;
          -  Related or unrelated cord blood units without full testing and negative results for&#xD;
             hepatitis A, B, C, HIV, HTLV-1, CMV viruses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Woolfrey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>January 3, 2011</last_update_submitted>
  <last_update_submitted_qc>January 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Woolfrey, Ann</name_title>
    <organization>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

